コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 angiotensin-converting enzyme inhibitor for left ventricular dysfunction).
2 as evolution to heart failure or symptomatic left ventricular dysfunction.
3 th pulmonary hypertension caused by systolic left ventricular dysfunction.
4 nd develop significant myocardial injury and left ventricular dysfunction.
5 charide (O55B5, 10 mg/kg), inducing systolic left ventricular dysfunction.
6 include progressive heart failure and severe left ventricular dysfunction.
7 1), can attenuate age-dependent induction of left ventricular dysfunction.
8 failure, pneumonia, atrial fibrillation, and left ventricular dysfunction.
9 and efficacy of TAVI in patients with severe left ventricular dysfunction.
10 art failure patients across the continuum of left ventricular dysfunction.
11 , and 11 patients who developed grade 2 or 3 left ventricular dysfunction.
12 eling of these structures despite persistent left ventricular dysfunction.
13 ity in heart failure across the continuum of left ventricular dysfunction.
14 sildenafil treatment ameliorated DOX-induced left ventricular dysfunction.
15 eterioration of HF in patients with systolic left ventricular dysfunction.
16 ventricular ejection fraction, and regional left ventricular dysfunction.
17 nd oxidative stress, which may contribute to left ventricular dysfunction.
18 d by presence of coronary artery disease and left ventricular dysfunction.
19 onship is linear with respect to severity of left ventricular dysfunction.
20 T inducibility in patients with prior MI and left ventricular dysfunction.
21 y risk in patients with coronary disease and left ventricular dysfunction.
22 hormonal activation, could result in further left ventricular dysfunction.
23 elial exocytosis, myocardial infarction, and left ventricular dysfunction.
24 ients with known coronary artery disease and left ventricular dysfunction.
25 in patients with coronary artery disease and left ventricular dysfunction.
26 in patients with coronary artery disease and left ventricular dysfunction.
27 dependent on valvular function or related to left ventricular dysfunction.
28 ardiac death (SCD) in patients with ischemic left ventricular dysfunction.
29 ition to expected haemodynamic sequelae from left ventricular dysfunction.
30 uding severe obstructive airways disease and left ventricular dysfunction.
31 ity for PCI and in patients with diabetes or left ventricular dysfunction.
32 y a role in development of postresuscitation left ventricular dysfunction.
33 inhibitors remain the first-line therapy for left ventricular dysfunction.
34 apillary pulmonary hypertension secondary to left ventricular dysfunction.
35 rs as part of the treatment of patients with left ventricular dysfunction.
36 heart failure and post-myocardial infarction left ventricular dysfunction.
37 ion for the treatment of chronic symptomatic left ventricular dysfunction.
38 e heart failure in patients with symptomatic left ventricular dysfunction.
39 not cause loss of body weight, lethality, or left ventricular dysfunction.
40 the plasma level of apelin in patients with left ventricular dysfunction.
41 We identified and screened 100 probands with left ventricular dysfunction.
42 eart failure and may aid in the detection of left ventricular dysfunction.
43 ssion to mediate the myocardial fibrosis and left ventricular dysfunction.
44 creases myocardial fibrosis and improves the left ventricular dysfunction.
45 with coronary artery disease and significant left ventricular dysfunction.
46 tively low 30-day mortality in patients with left ventricular dysfunction.
47 lity and heart failure (HF) in patients with left ventricular dysfunction.
48 art provokes left ventricular remodeling and left ventricular dysfunction.
49 occurs in the myocardium and correlates with left ventricular dysfunction.
50 , hypertrophy-related signal activation, and left ventricular dysfunction.
51 rget DLST are important metabolic players in left ventricular dysfunction.
52 ith, and possibly contributing to, diastolic left ventricular dysfunction.
53 ification beyond clinical data and degree of left ventricular dysfunction.
54 d medical therapy for patients with ischemic left ventricular dysfunction.
55 yocardial infarction characterized by severe left ventricular dysfunction.
56 because of old age, comorbidities, or severe left ventricular dysfunction.
57 ition to persistent AF, with no evidence for left ventricular dysfunction.
58 is, familial cardiomyopathy, and severity of left ventricular dysfunction.
59 ents with stable coronary artery disease and left-ventricular dysfunction.
60 in patients with coronary artery disease and left-ventricular dysfunction.
61 lysis using an experimental model of chronic left-ventricular dysfunction.
62 graphy to show that MHC-Angptl4 mice develop left-ventricular dysfunction.
63 tions in the myocardial substrate underlying left-ventricular dysfunction.
64 the intracoronary route in 17 patients with left ventricular dysfunction 1.5 to 3 months after myoca
65 .4 [1.6-3.9]), septic shock (2.7 [1.5-4.8]), left ventricular dysfunction (2.7 [1.6-5.0]), administra
67 VAs were older and had higher prevalence of left ventricular dysfunction (67% versus 13% of fascicul
69 NOS3 as a key mediator in the development of left ventricular dysfunction after administration of dox
71 safety of such an approach in patients with left ventricular dysfunction after myocardial infarction
72 sts in stable heart failure outpatients with left ventricular dysfunction after myocardial infarction
73 ear in stable heart failure outpatients with left ventricular dysfunction after myocardial infarction
76 We evaluated 19 patients who presented with left ventricular dysfunction after sudden emotional stre
77 f secondary mitral regurgitation (MR) due to left ventricular dysfunction, also known as functional M
78 racyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart fa
80 renergic receptor (betaAR) polymorphisms and left ventricular dysfunction-an important cause of allog
81 chronization therapy in patients with severe left ventricular dysfunction and a QRS duration <120 mil
82 For example, whereas uninsured patients with left ventricular dysfunction and CAD were less likely to
83 ancer therapy agents with the development of left ventricular dysfunction and cardiomyopathy, is an i
85 ion in patients with heart failure caused by left ventricular dysfunction and could be the first in c
86 to be expressed in adult mice (V1A-TG(Ind)), left ventricular dysfunction and dilatation were also se
87 rvival in a broad selection of patients with left ventricular dysfunction and either demonstrated or
88 ement before PCI in all patients with severe left ventricular dysfunction and extensive coronary dise
89 nostic information in patients with ischemic left ventricular dysfunction and has comparable accuracy
90 one may have clinical value in patients with left ventricular dysfunction and heart failure as first-
91 myocardial infarction (AMI) with subsequent left ventricular dysfunction and heart failure continues
96 th pulmonary hypertension caused by systolic left ventricular dysfunction and improved cardiac index
97 nfants and children with CHF attributable to left ventricular dysfunction and in infants with large l
98 is recommended in patients with symptoms of left ventricular dysfunction and in other settings, but
99 syndrome (TTS) is characterized by an acute left ventricular dysfunction and is associated with life
100 mation in the heart is sufficient to provoke left ventricular dysfunction and left ventricular remode
101 mitral valve repair to CABG in patients with left ventricular dysfunction and moderate to severe MR m
102 symptomatic high-risk patients with ischemic left ventricular dysfunction and multivessel coronary ar
103 ransient left ventricular apical ballooning, left ventricular dysfunction and normal or near-normal c
104 regulatable wild-type GSK-3beta mice induced left ventricular dysfunction and premature death, accomp
106 ho did not have these comorbidities, whereas left ventricular dysfunction and prior cardiac operation
107 inhibited interstitial fibrosis, decreasing left ventricular dysfunction and regional hypocontractil
108 thelial function was associated with reduced left ventricular dysfunction and remodeling, as well as
112 After a 5-year follow-up in patients with left ventricular dysfunction and suspected CAD, overall,
113 tic importance of WRF, 2231 patients who had left ventricular dysfunction and were enrolled in the Su
114 iabetes mellitus, a positive troponin assay, left-ventricular dysfunction and regional wall motion ab
115 of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of s
116 atients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 bea
117 s that include atrial fibrillation, profound left ventricular dysfunction, and after mechanical prost
118 ents with large acute myocardial infarction, left ventricular dysfunction, and at high risk of develo
119 ime of the AMI, older age, lower hemoglobin, left ventricular dysfunction, and chronic heart failure.
120 , gender, type of surgery, emergent surgery, left ventricular dysfunction, and diabetes mellitus), st
121 n cardiac fibroblasts leads to fibrogenesis, left ventricular dysfunction, and excessive scarring in
122 n cardiac fibroblasts leads to fibrogenesis, left ventricular dysfunction, and excessive scarring in
123 associated with increased CACS, subclinical left ventricular dysfunction, and increased pulse pressu
124 rupture, accentuates post-MI remodeling and left ventricular dysfunction, and increases the progress
125 n patients with mild heart-failure symptoms, left ventricular dysfunction, and left bundle-branch blo
126 troke or transient ischemic attack, smoking, left ventricular dysfunction, and mitral regurgitation.
127 such as acute respiratory distress syndrome, left ventricular dysfunction, and pulmonary embolism, as
128 ers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have s
129 haracterized by progression toward dilation, left ventricular dysfunction, and refractory heart failu
130 total and sudden deaths, conduction defects, left ventricular dysfunction, and supraventricular arrhy
131 ients with mildly symptomatic heart failure, left ventricular dysfunction, and wide QRS complex compa
132 R with history of ventricular tachycardia or left ventricular dysfunction appear to be associated wit
134 many mechanisms contributing to progressive left ventricular dysfunction are matched by stem cell ac
136 1 were significant univariable predictors of left ventricular dysfunction as assessed by an ejection
137 sis identifies diabetes and heart failure or left ventricular dysfunction as potential risk factors f
140 receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after myocard
141 titioning of dietary fatty acids (DFAs) with left ventricular dysfunction, both of which are improved
142 th trastuzumab; three patients had recurrent left ventricular dysfunction, but 22 patients (88%) did
143 iously documented coronary artery disease or left ventricular dysfunction, but blacks had more preval
144 tropic and lusitropic effects in humans with left ventricular dysfunction, but does not alter the for
145 in patients with coronary artery disease and left ventricular dysfunction, but this relationship was
146 NRIL and KCNQ1OT1 improved the prediction of left ventricular dysfunction by a model, including demog
147 Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study, which en
148 ted CB ablation decreases the progression of left ventricular dysfunction, cardiac remodeling, and ar
149 including guideline-directed medication for left ventricular dysfunction, cardiac resynchronization
151 ccurred in 16 patients (8%) and 37 (16%) had left ventricular dysfunction, defined as left ventricula
152 marker levels, and transient apical systolic left ventricular dysfunction despite the absence of obst
154 on by sitagliptin protected against ischemic left ventricular dysfunction during dobutamine stress in
155 the prevention and management of progressive left ventricular dysfunction during long-term follow-up.
156 e patients (age 64 +/- 10 years, n = 13 with left ventricular dysfunction) during ablation procedures
158 f hypertension, prior revascularization, and left ventricular dysfunction (ejection fraction <40%), a
159 erwent successful stenting for STEMI and had left ventricular dysfunction (ejection fraction</=48%) >
160 erwent successful stenting for STEMI and had left ventricular dysfunction (ejection fraction</=48%) >
163 ffects of CAD; late risk reflected diastolic left ventricular dysfunction expressed as ventricular hy
164 s) from donor mice with HF induced long-term left ventricular dysfunction, fibrosis, and hypertrophy
165 that can induce cardiac repair and attenuate left ventricular dysfunction from both within and outsid
167 th prediction over baseline risk factors and left ventricular dysfunction (global chi(2) 207.5 versus
168 heart failure (HF) subtended by progressive left ventricular dysfunction has received limited attent
171 cal dyssynchrony on outcome in patients with left ventricular dysfunction, heart failure, or both aft
173 er myocardial infarction among patients with left ventricular dysfunction, heart failure, or both.
174 tion by an experienced heart team to prevent left ventricular dysfunction, heart failure, reduced qua
175 rain echocardiography detects early signs of left ventricular dysfunction; however, it is unknown whe
176 10 to 1.97; p = 0.009), and heart failure or left ventricular dysfunction (HR: 1.32; 95% CI: 1.01 to
177 f prior myocardial infarction with resultant left ventricular dysfunction identifies a group at parti
178 ms, improves survival, and, in patients with left ventricular dysfunction, improves systolic function
180 ment with sildenafil prevented apoptosis and left ventricular dysfunction in a chronic model of doxor
181 ing infarct expansion, troponin release, and left ventricular dysfunction in a swine myocardial infar
182 cultured myocytes as well as hypertrophy and left ventricular dysfunction in experimental heart failu
183 , contributing to maladaptive remodeling and left ventricular dysfunction in hearts subjected to chro
186 al stress can precipitate severe, reversible left ventricular dysfunction in patients without coronar
187 ng revealed hypertrophic cardiomyopathy with left ventricular dysfunction in SKO mice, and these two
188 rosemide would accelerate the progression of left ventricular dysfunction in the "treated" group.
190 chemia/reperfusion injury and improvement of left ventricular dysfunction in the failing heart after
192 al vagal nerve stimulation (VNS) can improve left ventricular dysfunction in the setting of heart fai
195 ose presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during a
196 diomyocytes provoked cardiac hypertrophy and left ventricular dysfunction in vivo, whereas genetic kn
197 fy patients with coronary artery disease and left ventricular dysfunction in whom coronary-artery byp
198 ertrophy, dilated cardiomyopathy, and severe left ventricular dysfunction, including a marked reducti
204 Pulmonary hypertension caused by systolic left ventricular dysfunction is associated with signific
206 a potentially reversible condition in which left ventricular dysfunction is induced or mediated by a
207 (82)Rb PET is associated with more extensive left ventricular dysfunction, ischemic compromise, and r
209 tive procedure, even in patients with severe left ventricular dysfunction, leading to a high procedur
210 ng would not be attractive if a diagnosis of left ventricular dysfunction led to significant decrease
211 ongestion, and echocardiographic evidence of left ventricular dysfunction (left ventricle ejection fr
212 Evaluation (TIME) enrolled 120 patients with left ventricular dysfunction (left ventricular ejection
213 reated wild-type (WT) mice manifested severe left ventricular dysfunction, loss of heart and body mas
214 y the potential negative interaction between left ventricular dysfunction (LVD) and MSC activation.
215 ventricle of rabbit hearts with significant left ventricular dysfunction (LVD), 8-9 weeks after an a
218 survival among those with and without severe left ventricular dysfunction (LVD); 2) identify risk fac
220 no-flow ischemia, and these hearts developed left ventricular dysfunction manifested by an early and
221 -terminal BNP) to diagnose heart failure and left ventricular dysfunction, measurement of BNP and N-t
225 gh-grade atrioventricular block, significant left ventricular dysfunction, myocardial delayed enhance
226 etection Window Programming in Patients With Left Ventricular Dysfunction, Non-ischemic Etiology in P
227 ging, male sex, hypertension, valve disease, left ventricular dysfunction, obesity, and alcohol consu
228 sly unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding pa
229 with an increased risk of echocardiographic left ventricular dysfunction (odds ratio [OR], 1.3 per q
232 of patients demonstrated moderate or severe left ventricular dysfunction on initial echocardiogram (
235 for reasons that included coronary disease, left ventricular dysfunction or hypertrophy, and high-do
236 erican Heart Association class I indication (left ventricular dysfunction or medical history of heart
238 levated in children with CHF attributable to left ventricular dysfunction or pulmonary overcirculatio
239 ced by VPB grade, presence of recovery VPBs, left ventricular dysfunction, or an ischemic ST-segment
240 inical or radiologic signs of heart failure, left ventricular dysfunction, or both, and a documented
241 free of evidence of coronary artery disease, left ventricular dysfunction, or evident repolarization
242 that can present as acute coronary syndrome, left ventricular dysfunction, or potentially sudden card
243 tely-by precipitating myocardial infarction, left-ventricular dysfunction, or dysrhythmia; and chroni
245 iac death after accounting for risk factors, left ventricular dysfunction, pharmacological stress, an
246 a consecutive series of patients with severe left ventricular dysfunction, pLVAD-supported scar VT ab
247 fety and potential efficacy in patients with left ventricular dysfunction post STEMI who are at risk
251 nts: those with acute myocardial infarction, left ventricular dysfunction, previous history of stroke
252 chronization Reverses Remodeling in Systolic Left Ventricular Dysfunction], RAFT (Resynchronization-D
253 (28-66), seven males, none with a history of left ventricular dysfunction, received venoarterial extr
254 class I triggers (heart failure symptoms or left ventricular dysfunction) remains controversial in p
255 n for high-risk patients (e.g. patients with left ventricular dysfunction, reoperation, elderly, mult
256 tween patients with and without a history of left ventricular dysfunction resulting from KD-associate
257 in the management of patients with systolic left ventricular dysfunction (resulting from both ischem
258 f CDCs in a preclinical model of postinfarct left ventricular dysfunction results in formation of new
259 chronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evalua
260 chronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) was a multicenter
261 chronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) was a multicenter
262 tify four important abnormalities: asystole, left ventricular dysfunction, right ventricular dilation
263 s with clinically manifest CS, the extent of left ventricular dysfunction seems to be the most import
264 pathy (SCM) is a peculiar form of reversible left ventricular dysfunction seen predominantly in women
265 vents, although rare, may be associated with left ventricular dysfunction, severe pulmonary hypertens
266 sion experiments in 17 pigs with postinfarct left ventricular dysfunction showed CDC doses > or =10(7
268 In the 6,797 patients in the Studies Of Left Ventricular Dysfunction (SOLVD), we compared the ri
269 on the effect of enalapril in the Studies of Left Ventricular Dysfunction [SOLVD] Treatment Trial).
270 ocardium is common in patients with NQMI and left ventricular dysfunction, suggesting that aggressive
271 sidual TR was associated with age, right and left ventricular dysfunction, tethering distance and are
272 iving vasopressin had more postresuscitation left ventricular dysfunction than those receiving epinep
273 was amenable to CABG, and dominant anterior left ventricular dysfunction that was amenable to surgic
275 t, namely those with atrial fibrillation and left ventricular dysfunction, those with acute sustained
276 terogeneous group, ranging from asymptomatic left ventricular dysfunction to chronic decompensation w
277 role nesiritide might play in patients with left ventricular dysfunction undergoing coronary artery
280 A history of ventricular tachycardia and left ventricular dysfunction was associated with higher
281 jected to an ischaemia-reperfusion protocol, left ventricular dysfunction was associated with uncoupl
290 om pulmonary hypertension caused by systolic left ventricular dysfunction were randomized to double-b
291 9) with prior myocardial infarction (MI) and left ventricular dysfunction were referred for defibrill
292 lation more than 7 days, and severe systolic left ventricular dysfunction were stronger predictors of
293 tion, ineffective cough, and severe systolic left ventricular dysfunction were the three independent
294 ve generally a normal coronary angiogram and left ventricular dysfunction, which extends beyond the t
295 ces the risk stratification of patients with left ventricular dysfunction who are ICD candidates, it
296 of patients with coronary artery disease and left ventricular dysfunction who were enrolled in a rand
297 ADIT-II enrolled 1232 patients with ischemic left ventricular dysfunction who were randomized to ICD
298 rt Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spir
299 f 362 patients with ischemic cardiomyopathy (left ventricular dysfunction with >70% stenosis in >/=1
300 atients experienced some degree of segmental left ventricular dysfunction, with severity proportional
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。